AbbVie and Allergan have announced the Federal Trade Commission has accepted AbbVie's pending acquisition of Allergan for $63 billion.
List view / Grid view
Crohn's disease (CD)
Filter the results
Crohn’s disease is a type of inflammatory bowel disease that may affect any part of the gastrointestinal tract from mouth to anus. Signs and symptoms often include abdominal pain, diarrhea (which may be bloody if inflammation is severe), fever, and weight loss.
Other complications may occur outside the gastrointestinal tract and include anemia, skin rashes, arthritis, inflammation of the eye, and feeling tired. The skin rashes may be due to infections as well as pyoderma gangrenosum or erythema nodosum. Bowel obstruction also commonly occurs and those with the disease are at greater risk of bowel cancer.
Crohn’s disease is caused by a combination of environmental, immune and bacterial factors in genetically susceptible individuals. It results in a chronic inflammatory disorder, in which the body’s immune system attacks the gastrointestinal tract possibly directed at microbial antigens. While Crohn’s is an immune related disease, it does not appear to be an autoimmune disease (in that the immune system is not being triggered by the body itself). The exact underlying immune problem is not clear; however, it may be an immunodeficiency state. About half of the overall risk is related to genetics with more than 70 genes found to be involved.
The European Commission has granted marketing authorisation to Stelara (ustekinumab) to treat patients aged six to 11 with moderate to severe plaque psoriasis.
As the demand for safety-syringes increases, the market for pre-filled safety-engineered devices will increase. This article outlines the main drivers behind this growth.
Janssen has recently received marketing authorisation from the European Commission for Stelara to treat ulcerative colitis. Dr Jaime Oliver discusses the mode of action and why the treatment is needed.
The seven centres will aid disease research and clinical development, improving access to patient data for studies.
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
Eli Lilly presents new data for their mirikizimab treatment for Crohn’s disease.
A phase III clinical trial looks to use a patients own stem cells to treat the debilitating disease...
The EC has approved Alofisel for the treatment of complex perianal fistulae in adult patients with nonactive/mildly active luminal Crohn’s disease...
Researchers have found that cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, Crohn's disease and other medical issues...
Phase 3 clinical program for upadacitinib in atopic dermatitis, the most common type of eczema, is planned to begin in the first half of 2018...
The findings from the two pivotal phase 3 trials pave the way for ozanimod to enter the New Drug Approval process with the FDA...
A fast, simple blood test for ulcerative colitis using infrared spectroscopy may provide a cheaper, less invasive alternative for screening compared to colonoscopy...